23andMe Investor Day Presentation Deck
23andMe Immune-Oncology (I/O) Signature Highlights
Genetically-Driven Targets
Large I/O market with over
$41B expected in 2021 sales¹
2021 projected sales of leading
checkpoint inhibitors
KEYTRUDA
OPDIVO
YERVOY
$17.0B
$7.9B
$1.8B
1 Source: Evaluate Pharma historical and forecast estimates.
Global Immuno-Oncology Drug Development Pipeline
Published by Samik Upadhaya & Annie Yu on Sep 18, 2020
Sources: CRI, CRI Analytics, Clinicaltrials.gov, CRI-iAtlas, and GlobalData.
Target
CD19
TAA
PD-L1
PD-1
BCMA
HER2
4,720 agents and 504 targets in 2020.
CD3
CTLA-4
CD47
HPV
NY-ESO-1
4-1BB
CD20
MUC1
CD22
STING
STAT3
IFNAR1
IDO1
CSF1R
neoantigens
0
53
50
49
48
46
44
41
41
39
39
38
37
37
136
87
132
CANCER
The Anna-Maria Kellon
RESEARCH Clinical
INSTITUTE Accelerator
117
198
245
50 100 150 200 250 300
Number of active IO agents per target
>
23andMe's I/O signature
identifies targets that are
genetically-driven
↓ ↓
X X
3
↓
X
4
5
↓
Similarity classifier
↓ ↓ ↓
X X
Copyright © 2022 23andMe, Inc.
7
8
↓↓
↓
X
↓
X
↓
↓
X
23andMe
34View entire presentation